CGA
CYTO

Crescent Grove Advisors’s Altamira Therapeutics Ltd CYTO Stock Holding History

Crescent Grove Advisors’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3
Closed -$7K – 164
2019
Q1 		$7K Hold
3
– – ﹤0.01% 151
2018
Q4 		$9K Buy
+3
New +$15.3K ﹤0.01% 156

Other funds holding CYTO

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Crescent Grove Advisors's CYTO Position: Q2 2019 in Review

Crescent Grove Advisors sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2019, closing a stake of 3 shares — an estimated $7K sold.

Crescent Grove Advisors first reported a position in CYTO in Q4 2018 and held it in 2 quarters. The position peaked at $9K in Q4 2018. 5 funds tracked by Wall St. Rank hold CYTO as of Q2 2019.

  • Crescent Grove Advisors reported no remaining Altamira Therapeutics Ltd position as of Q2 2019 after selling out during the quarter.
  • Crescent Grove Advisors sold 3 Altamira Therapeutics Ltd shares in Q2 2019, an estimated $7K.
  • Crescent Grove Advisors first reported a position in Altamira Therapeutics Ltd in Q4 2018 and held it in 2 quarters.
  • Crescent Grove Advisors's Altamira Therapeutics Ltd position peaked at $9K in Q4 2018.
  • 5 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2019.

Based on Crescent Grove Advisors's 13F filing for Q2 2019, filed 6 Aug 2019.